Overview

Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2029-10-01

Target enrollment:

Participant gender:

Summary

The study for which participation is requested is a phase II clinical trial to assess the efficacy of dostarlimab as neoadjuvant therapy in patients with MMRd/MSI-H stage II-III endometrial cancer. The study is conducted in Spain with an estimated number of 25 patients for phase II. The main objective of this phase-II study is to evaluate the clinical complete response (cCR) after neoadjuvant therapy with dostarlimab.

Phase:

PHASE2

Details

Lead Sponsor:

Grupo Espaol de Investigacin en Cncer de Ovario

Collaborator:

GlaxoSmithKline

Treatments:

dostarlimab